Patents by Inventor Karen B. Chapman

Karen B. Chapman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210102251
    Abstract: The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells. Assays useful in identifying human embryonic stem cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length are described as well as quality control assays for screening genomic integrity in cells expanded and banked for therapeutic use, as well as assays to identify cells capable of abnormal immortalization.
    Type: Application
    Filed: July 22, 2020
    Publication date: April 8, 2021
    Inventors: Michael G. WEST, Karen B. CHAPMAN, Walter D. FUNK
  • Patent number: 10745752
    Abstract: The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells. Assays useful in identifying human embryonic stem cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length are described as well as quality control assays for screening genomic integrity in cells expanded and banked for therapeutic use, as well as assays to identify cells capable of abnormal immortalization.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: August 18, 2020
    Inventors: Michael D. West, Karen B. Chapman, Walter D. Funk
  • Publication number: 20200181567
    Abstract: This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.
    Type: Application
    Filed: October 25, 2019
    Publication date: June 11, 2020
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent
  • Patent number: 10501723
    Abstract: This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: December 10, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent
  • Publication number: 20180170982
    Abstract: The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and indentified formulations for research and therapeutic purposes.
    Type: Application
    Filed: July 12, 2017
    Publication date: June 21, 2018
    Applicant: BioTime, Inc.
    Inventors: Michael D. West, Karen B. Chapman
  • Publication number: 20170335392
    Abstract: The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells. Assays useful in identifying human embryonic stem cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length are described as well as quality control assays for screening genomic integrity in cells expanded and banked for therapeutic use, as well as assays to identify cells capable of abnormal immortalization.
    Type: Application
    Filed: May 23, 2016
    Publication date: November 23, 2017
    Inventors: Michael D. West, Karen B. Chapman, Walter D. Funk
  • Patent number: 9732128
    Abstract: The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and identified formulations for research and therapeutic purposes.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: August 15, 2017
    Assignee: BioTime, Inc.
    Inventors: Michael D. West, Karen B. Chapman
  • Publication number: 20170226475
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 10, 2017
    Inventor: Karen B. Chapman
  • Publication number: 20170152475
    Abstract: This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.
    Type: Application
    Filed: October 28, 2014
    Publication date: June 1, 2017
    Applicant: Advanced Cell Technology, Inc.
    Inventors: Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent
  • Patent number: 9580683
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: February 28, 2017
    Assignee: Advanced Cell Technology, Inc.
    Inventor: Karen B. Chapman
  • Publication number: 20170003278
    Abstract: The invention relates to assays for screening growth factors, adhesion molecules, immunostimulatory molecules, extracellular matrix components and other materials, alone or in combination, simultaneously or temporally, for the ability to induce directed differentiation of pluripotent and multipotent stem cells.
    Type: Application
    Filed: April 29, 2016
    Publication date: January 5, 2017
    Inventors: Michael D. West, Raymond L. Page, Hans Schoeler, Karen B. Chapman
  • Publication number: 20160263203
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: December 30, 2015
    Publication date: September 15, 2016
    Inventors: THOMAS R. CECH, JOACHIM LINGNER, TORU M. NAKAMURA, KAREN B. CHAPMAN, GREGG B. MORIN, CALVIN B. HARLEY, WILLIAM H. ANDREWS
  • Patent number: 9334478
    Abstract: The invention relates to assays for screening growth factors, adhesion molecules, immunostimulatory molecules, extracellular matrix components and other materials, alone or in combination, simultaneously or temporally, for the ability to induce directed differentiation of pluripotent and multipotent stem cells.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: May 10, 2016
    Assignee: Advanced Cell Technology, Inc.
    Inventors: Michael D. West, Raymond L. Page, Hans Schoeler, Karen B. Chapman
  • Publication number: 20150250863
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: February 25, 2014
    Publication date: September 10, 2015
    Applicants: The Regents of the University of Colorado, Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Publication number: 20150232808
    Abstract: This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.
    Type: Application
    Filed: October 28, 2014
    Publication date: August 20, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventors: Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent
  • Publication number: 20150132853
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 14, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventor: Karen B. Chapman
  • Patent number: 8709995
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 29, 2014
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Patent number: 8685386
    Abstract: Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for >40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: April 1, 2014
    Assignee: BioTime, Inc
    Inventors: Michael D. West, Hal Sternberg, Karen B. Chapman
  • Publication number: 20140057348
    Abstract: The present invention provides methods for the culture of animal pluripotent stem cells and their differentiated progeny cells, tissues, and organs, and nonhuman animal embryos and fetuses.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 27, 2014
    Applicant: ADVANCED CELL TECHNOLOGY, INC.
    Inventors: Michael D. West, Karen B. Chapman, Irina V. Klimanskaya
  • Patent number: 8597944
    Abstract: The present invention provides methods for the culture of animal pluripotent stem cells and their differentiated progeny cells, tissues, and organs, and nonhuman animal embryos and fetuses.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: December 3, 2013
    Assignee: Advanced Cell Technology, Inc.
    Inventors: Michael D. West, Karen B. Chapman, Irina V. Klimanskaya